Hound Partners’s Keros Therapeutics KROS Stock Holding History

Hound Partners’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-25,000	Closed	-$989K	–	120
2021 Q3	$989K	Buy	+25,000	New	+$890K	0.05%	143

Other funds holding KROS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Hound Partners's KROS Position: Q4 2021 in Review

Hound Partners sold out of Keros Therapeutics (KROS) in Q4 2021, closing a stake of 25,000 shares — an estimated $989K sold.

Hound Partners first reported a position in KROS in Q3 2021 and held it in 1 quarter. The position peaked at $989K in Q3 2021. 99 funds tracked by Wall St. Rank hold KROS as of Q4 2021.

Hound Partners reported no remaining Keros Therapeutics position as of Q4 2021 after selling out during the quarter.
Hound Partners sold 25,000 Keros Therapeutics shares in Q4 2021, an estimated $989K.
Hound Partners first reported a position in Keros Therapeutics in Q3 2021 and held it in 1 quarter.
Hound Partners's Keros Therapeutics position peaked at $989K in Q3 2021.
99 funds tracked by Wall St. Rank held Keros Therapeutics as of Q4 2021.

Based on Hound Partners's 13F filing for Q4 2021, filed 14 Feb 2022.